Barcelona Children’s Hospital Sant Joan de Déu (HSJD): Health Data and ATMPs for Personalised Medicine

Hospital Sant Joan de Déu (HSJD) is a paediatric hospital based in Catalonia (Spain) with experience in health data infrastructures and advanced therapies, and an interest in exploring interregional collaboration opportunities under PRECISEU.

HSJD has ongoing initiatives related to the secondary use of health data, data-driven hospital management and advanced therapies development, which could potentially contribute to future Innovation Actions at TRL 6–8.

At this stage, HSJD is interested in connecting with potential partners to explore ideas and assess possible alignment with PRECISEU priorities.

Health Data – secondary use and data-driven healthcare

HSJD has developed a solid strategy for the secondary use of health data combining operational, clinical and research needs. The hospital operates a hybrid data architecture, integrating a Data Warehouse for healthcare management and a GDPR-compliant Data Lake designed to support research and innovative data-driven solutions.

Building on this infrastructure, HSJD has launched CORTEX, a hospital-wide data analytics and intelligence initiative that integrates multiple data sources and applies AI-based models to support clinical and operational decision-making. CORTEX enables real-time monitoring, predictive analysis and optimisation of care processes, and represents a potential scalable and transferable model aligned with interoperability and EHDS-related objectives.

Advanced Therapies (ATMPs)

HSJD hosts a GMP-certified Advanced Therapies Platform, authorised to manufacture CAR‑T cell therapies for both paediatric and adult patients, in compliance with EMA quality standards. The platform covers the full translational pathway, from preclinical research to clinical-grade manufacturing of cell, gene and tissue-engineered therapies.

The infrastructure is open to collaboration with other hospitals, research institutions and industry, and is integrated in regional, national and European networks on advanced therapies. This positions HSJD as a potential partner for translational, validation and implementation-focused ATMP projects within an interregional context.

We offer:

• mature digital health and data infrastructures,

• GMP-certified ATMP manufacturing capabilities,

• real-world clinical environments for validation,

• experience in European and interregional collaboration,

• strong alignment with PRECISEU priorities and funding regions.